Walgreens Boots Alliance Gestione

Gestione criteri di controllo 1/4

Walgreens Boots Alliance Il CEO è Tim Wentworth, nominato in Oct2023, ha un mandato di 1.08 anni. possiede direttamente 0.019% delle azioni della società, per un valore di € 1.33M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 3.1 anni.

Informazioni chiave

Tim Wentworth

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.1yrs
Proprietà del CEO	0.02%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	3.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Tim Wentworth (64 yo)

1.1yrs

Mandato

Mr. Timothy C. Wentworth, also known as Tim, served as Director of Ushur, Inc. since February 2022. He served as the Chief Executive Officer of Evernorth at Evernorth Health, Inc. (formerly known as Expres...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stefano Pessina	Executive Chairman of the Board	12.6yrs	US$7.57m	0.096% € 6.9m
Manmohan Mahajan	Executive VP & Global CFO	1.3yrs	US$1.83m	0.048% € 3.4m
Ornella Barra	Chief Operating Officer of International	no data	US$5.43m	0.25% € 17.8m
Timothy Wentworth	CEO & Director	1.1yrs	Nessun dato	0.019% € 1.3m
Todd Heckman	Senior VP	1.3yrs	Nessun dato	0.0019% € 137.2k
Neal Sample	Executive VP & Chief Information Officer	less than a year	Nessun dato	0.0066% € 470.3k
Tiffany Kanaga	Vice President of Global Investor Relations	no data	Nessun dato	Nessun dato
Matthew D'Ambrosio	Senior VP and Global Chief Compliance & Ethics Officer	no data	Nessun dato	Nessun dato
Lanesha Minnix	Executive VP & Global Chief Legal Officer	less than a year	Nessun dato	Nessun dato
Elizabeth Burger	Executive VP & Chief Human Resources Officer	no data	Nessun dato	Nessun dato
Liyue Wu	Head of M&A - Asia	no data	Nessun dato	Nessun dato
Tracey Brown	Executive VP	3yrs	Nessun dato	0.0087% € 620.4k

1.3yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di W8A non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stefano Pessina	Executive Chairman of the Board	12.6yrs	US$7.57m	0.096% € 6.9m
Timothy Wentworth	CEO & Director	1.1yrs	Nessun dato	0.019% € 1.3m
Ginger Graham	Lead Independent Director	14.6yrs	US$366.85k	0.00025% € 17.9k
Valerie Jarrett	Independent Director	4.1yrs	US$300.00k	0.00052% € 37.2k
Nancy Schlichting	Independent Director	18.1yrs	US$319.97k	0.0024% € 175.1k
John Lederer	Independent Director	9.6yrs	US$315.00k	0.0058% € 413.1k
Bryan Hanson	Independent Director	2.1yrs	US$84.62k	0.0036% € 255.1k
Janice Babiak	Independent Director	12.6yrs	US$325.00k	0.00014% € 10.0k
William Shrank	Director	less than a year	Nessun dato	0.00041% € 29.3k
Inderpal Bhandari	Independent Director	2.2yrs	US$115.29k	0.00035% € 25.0k
Thomas Polen	Director	1.3yrs	US$14.13k	0.0019% € 136.5k
Robert Huffines	Independent Director	less than a year	Nessun dato	Nessun dato

3.1yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di W8A sono considerati esperti (durata media dell'incarico 3.1 anni).

Walgreens Boots Alliance Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Walgreens Announces Executive Appointments

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Recent updates

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on December 12, 2024

Walgreens Boots Alliance, Inc. Expects to Close Approximately 1,200 Stores over the Next 3 Years with About 500 Targeted to Close in Fiscal 2025

Full year 2024 earnings released: US$10.01 loss per share (vs US$3.57 loss in FY 2023)

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2025

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Saxena White P.A. Files New Securities Fraud Class Action Lawsuit Against Walgreens Boots Alliance, Inc. and Certain of its Executives

Walgreens Boots Alliance, Inc. to Report Q4, 2024 Results on Oct 15, 2024

Walgreens Announces Executive Appointments

Upcoming dividend of US$0.25 per share

Gross Law Firm Announces Lawsuit Against Walgreens Boots Alliance, Inc

Third quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on September 12, 2024

Boots Chief Quits Reportedly After Walgreens' Sale Plan Stalls

Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.14 in 3Q 2023)

Walgreens Boots Alliance, Inc. to Report Q3, 2024 Results on Jun 27, 2024

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought €313k worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold €640k worth of stock

Upcoming dividend of US$0.48 per share

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments